CGEN Compugen Ltd.

NASDAQ
$2.41

Compugen Ltd. (CGEN) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.0% since its last earnings release on August 3, 2026.

Compugen Reported In-line with Estimates
Monday, August 3, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.07)
Rev est $2.7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.39

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Compugen Ltd.

Compugen Ltd is a drug discovery and development company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.

Sector

Healthcare

Industry

Biotechnology